[시장보고서]세계의 자궁암 진단 검사 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

세계의 자궁암 진단 검사 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Uterine Cancer Diagnostic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

상품코드 : 1631384

리서치사 : Persistence Market Research

발행일 : 2025년 01월

페이지 정보 : 영문 241 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,249,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,587,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,329,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 자궁암 진단 검사 시장 규모는 2025년 35억 4,710만 달러에 달할 것으로 보이며, 2025-2032년의 예측 기간에 9.60%의 연평균 복합 성장률(CAGR)로 확대되고, 2032년에는 67억 3,890만 달러에 도달할 것으로 예상됩니다.

세계의 자궁암 진단 검사 시장은 자궁내막암이나 자궁육종을 포함한 자궁체암의 검출을 목적으로 한 초음파검사, 생검법, 혈액검사 등의 진단 솔루션으로 구성됩니다. 성장의 원동력은 자궁체암의 유병률 증가, 진단 기술의 진보, 고령자 인구 증가입니다.

몇몇 요인이 세계의 자궁암 진단 검사 시장의 성장을 가속하고 있습니다 특히 폐경 후나 비만의 여성 사이에서 자궁체암의 유병률이 상승하고 있는 것이, 조기 발견법 수요를 강조하고 있습니다. 시장 도입에 박차를 가하고 있습니다 특히 신흥 경제 국가에서의 건강 관리 지출 증가는 진단 솔루션의 개발과 이용 용이성을 지원하고 있습니다. 정부의 이니셔티브와 조기 진단에 대한 의식이 높아짐에 따라 시장 성장에 크게 기여합니다.

자궁암 진단 검사 시장은 기술의 진보와 헬스케어 액세스의 확대에 의해 큰 성장 기회를 제공합니다. 낮은 침습 진단 도구의 개발은 환자의 컴플라이언스를 높이고 시장의 확산을 확대합니다. 신흥국은 헬스케어 인프라에 대한 투자 증가와 암 검진에 대한 정부의 지원 이니셔티브에 의해 미개척의 가능성을 지니고 있습니다. 진단 솔루션 제공업체와 의료 기관의 파트너십은 혁신을 가속화하고 서비스 제공을 확대할 수 있습니다. 또한, 맞춤형 의료 및 정밀 진단에 대한 관심 증가는 시장 확대의 새로운 길을 제공합니다.

본 보고서에서는 세계의 자궁암 진단 검사 시장에 대해 조사했으며, 암 유형별, 진단 검사 유형별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

영문목차

Persistence Market Research has recently released a comprehensive report on the global Uterine Cancer Diagnostic Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Uterine Cancer Diagnostic Testing Market Size (2025E): US$ 3,547.10 Mn
Projected Market Value (2032F): US$ 6,738.90 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 9.60%

Uterine Cancer Diagnostic Testing Market - Report Scope:

The global uterine cancer diagnostic testing market comprises diagnostic solutions such as ultrasound scanning, biopsy procedures, and blood tests aimed at detecting uterine cancer, which includes endometrial carcinoma and uterine sarcoma. The market growth is driven by the increasing prevalence of uterine cancer, advancements in diagnostic technologies, and the rising geriatric population. Improved healthcare infrastructure, awareness programs, and government initiatives also support market expansion.

Market Drivers:

Several factors are propelling the growth of the global uterine cancer diagnostic testing market. The rising prevalence of uterine cancer, particularly among post-menopausal and obese women, underscores the demand for early detection methods. Advances in diagnostic techniques, such as transvaginal ultrasound scanning and CA125 tumor marker blood tests, have improved accuracy and reliability, fueling market adoption. Increasing healthcare expenditure, especially in emerging economies, supports the development and accessibility of diagnostic solutions. Furthermore, government initiatives promoting women's health and cancer screenings, combined with rising awareness about early diagnosis, contribute significantly to market growth.

Market Restraints:

Despite the promising growth trajectory, the uterine cancer diagnostic testing market faces several challenges. High costs associated with advanced diagnostic procedures and limited healthcare infrastructure in certain regions can hinder market penetration. Awareness about uterine cancer diagnosis remains low in developing countries, impacting timely detection and treatment. The complexity and invasiveness of certain diagnostic procedures, such as dilation and curettage, may deter patients, particularly in regions with cultural and social barriers to medical intervention.

Market Opportunities:

The uterine cancer diagnostic testing market offers significant growth opportunities driven by technological advancements and expanding healthcare access. Development of minimally invasive diagnostic tools enhances patient compliance and broadens market adoption. Emerging economies present untapped potential due to increasing investments in healthcare infrastructure and government-backed initiatives for cancer screenings. Partnerships between diagnostic solution providers and healthcare organizations can accelerate innovation and expand service delivery. Additionally, the growing focus on personalized medicine and precision diagnostics provides new avenues for market expansion.

Key Questions Answered in the Report:

1. What are the primary factors driving the global growth of the uterine cancer diagnostic testing market?

2. Which diagnostic solutions are gaining the highest adoption across different regions?

3. How are advancements in diagnostic technologies shaping the competitive landscape of the uterine cancer diagnostic testing market?

4. Who are the key players in the uterine cancer diagnostic testing market, and what strategies are they employing to maintain their market positions?

5. What are the emerging trends and future outlooks for the global uterine cancer diagnostic testing market?

Competitive Intelligence and Business Strategy:

Leading companies in the global uterine cancer diagnostic testing market, such as Siemens Healthineers, Hologic, and GE Healthcare, are focusing on technological innovations and expanding their product portfolios to gain a competitive edge. These companies are leveraging collaborations with healthcare providers and research institutions to accelerate the development of advanced diagnostic solutions. Investments in AI-based imaging and non-invasive diagnostic technologies further support market growth. Additionally, companies are emphasizing affordability and accessibility to cater to diverse patient demographics, particularly in emerging economies.

Key Companies Profiled:

Abbott
Roche Holdings AG
Siemens AG
Danaher
BioMerieux SA
Others

Uterine Cancer Diagnostic Testing Market Segmentation:

By Cancer Type:

Endometrial Carcinoma
Uterine Sarcoma

By Diagnostic Test Type:

Ultrasound Scanning
Biopsy Procedures
Blood Tests

By End User:

Hospitals
Ambulatory Surgical Centers
Cancer Research Institutes
Specialized Clinics
Diagnostic Laboratories

By Region:

North America
Europe
Latin America
South East Asia & Pacific
Middle East & Africa (MEA)
China
Japan

1. Executive Summary

1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Definition
2.2. Market Taxonomy

3. Uterine Cancer Diagnostic Testing Market View Point

3.1. Macro-Economic Factors
3.2. Market Drivers and Restraints
3.3. Opportunity Analysis
3.4. Global Key trends
3.5. Reimbursement Scenario

4. Global Uterine Cancer Diagnostic Testing Market - Key Inclusions

4.1. Regional Average Pricing Analysis
4.2. Parent Market Assessment
4.3. Epidemiology

5. North America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

5.1. Introduction
5.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 5.2.1. U.S.
- 5.2.2. Canada
5.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 5.3.1. U.S.
- 5.3.2. Canada
5.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 5.4.1. Uterine Sarcoma
- 5.4.2. Endometrial Carcinomas
5.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 5.5.1. Uterine Sarcoma
- 5.5.2. Endometrial Carcinomas
5.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 5.6.1. Ultrasound Scanning
  - 5.6.1.1. Abdominal Ultrasound
  - 5.6.1.2. Transvaginal Ultrasound
- 5.6.2. Biopsy
  - 5.6.2.1. Endometrial Biopsy
  - 5.6.2.2. Hysteroscopy
  - 5.6.2.3. Dilation and curettage
- 5.6.3. Blood tests
  - 5.6.3.1. Complete blood Count
  - 5.6.3.2. CA-125 blood test
5.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 5.7.1. Ultrasound Scanning
  - 5.7.1.1. Abdominal Ultrasound
  - 5.7.1.2. Transvaginal Ultrasound
- 5.7.2. Biopsy
  - 5.7.2.1. Endometrial Biopsy
  - 5.7.2.2. Hysteroscopy
  - 5.7.2.3. Dilation and curettage
- 5.7.3. Blood tests
  - 5.7.3.1. Complete blood Count
  - 5.7.3.2. CA-125 blood test
5.8. Historical Market Size Analysis 2019 - 2024, By End User
- 5.8.1. Hospitals
- 5.8.2. Ambulatory Surgical Centers
- 5.8.3. Cancer Research Centers
- 5.8.4. Specialized Clinics
- 5.8.5. Diagnostic Laboratories
- 5.8.6. Others
5.9. Market Size Analysis 2025 - 2032, By End User
- 5.9.1. Hospitals
- 5.9.2. Ambulatory Surgical Centers
- 5.9.3. Cancer Research Centers
- 5.9.4. Specialized Clinics
- 5.9.5. Diagnostic Laboratories
- 5.9.6. Others
5.10. Drivers and Restraints: Impact Analysis
5.11. Market Attractiveness Analysis
- 5.11.1. By Cancer Type
- 5.11.2. By Test Type
- 5.11.3. By End user
- 5.11.4. By Country

6. Latin America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

6.1. Introduction
6.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 6.2.1. Brazil
- 6.2.2. Mexico
- 6.2.3. Rest of Latin America
6.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 6.3.1. Brazil
- 6.3.2. Mexico
- 6.3.3. Rest of Latin America
6.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 6.4.1. Uterine Sarcoma
- 6.4.2. Endometrial Carcinomas
6.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 6.5.1. Uterine Sarcoma
- 6.5.2. Endometrial Carcinomas
6.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 6.6.1. Ultrasound Scanning
  - 6.6.1.1. Abdominal Ultrasound
  - 6.6.1.2. Transvaginal Ultrasound
- 6.6.2. Biopsy
  - 6.6.2.1. Endometrial Biopsy
  - 6.6.2.2. Hysteroscopy
  - 6.6.2.3. Dilation and curettage
- 6.6.3. Blood tests
  - 6.6.3.1. Complete blood Count
  - 6.6.3.2. CA-125 blood test
6.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 6.7.1. Ultrasound Scanning
  - 6.7.1.1. Abdominal Ultrasound
  - 6.7.1.2. Transvaginal Ultrasound
- 6.7.2. Biopsy
  - 6.7.2.1. Endometrial Biopsy
  - 6.7.2.2. Hysteroscopy
  - 6.7.2.3. Dilation and curettage
- 6.7.3. Blood tests
  - 6.7.3.1. Complete blood Count
  - 6.7.3.2. CA-125 blood test
6.8. Historical Market Size Analysis 2019 - 2024, By End User
- 6.8.1. Hospitals
- 6.8.2. Ambulatory Surgical Centers
- 6.8.3. Cancer Research Centers
- 6.8.4. Specialized Clinics
- 6.8.5. Diagnostic Laboratories
- 6.8.6. Others
6.9. Market Size Analysis 2025 - 2032, By End User
- 6.9.1. Hospitals
- 6.9.2. Ambulatory Surgical Centers
- 6.9.3. Cancer Research Centers
- 6.9.4. Specialized Clinics
- 6.9.5. Diagnostic Laboratories
- 6.9.6. Others
6.10. Drivers and Restraints: Impact Analysis
6.11. Market Attractiveness Analysis
- 6.11.1. By Cancer Type
- 6.11.2. By Test Type
- 6.11.3. By End user
- 6.11.4. By Country

7. Europe Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

7.1. Introduction
7.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 7.2.1. Germany
- 7.2.2. U.K.
- 7.2.3. France
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Poland
- 7.2.7. Russia
- 7.2.8. Rest of Europe
7.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 7.3.1. Germany
- 7.3.2. U.K.
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Poland
- 7.3.7. Russia
- 7.3.8. Rest of Europe
7.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 7.4.1. Uterine Sarcoma
- 7.4.2. Endometrial Carcinomas
7.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 7.5.1. Uterine Sarcoma
- 7.5.2. Endometrial Carcinomas
7.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 7.6.1. Ultrasound Scanning
  - 7.6.1.1. Abdominal Ultrasound
  - 7.6.1.2. Transvaginal Ultrasound
- 7.6.2. Biopsy
  - 7.6.2.1. Endometrial Biopsy
  - 7.6.2.2. Hysteroscopy
  - 7.6.2.3. Dilation and curettage
- 7.6.3. Blood tests
  - 7.6.3.1. Complete blood Count
  - 7.6.3.2. CA-125 blood test
7.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 7.7.1. Ultrasound Scanning
  - 7.7.1.1. Abdominal Ultrasound
  - 7.7.1.2. Transvaginal Ultrasound
- 7.7.2. Biopsy
  - 7.7.2.1. Endometrial Biopsy
  - 7.7.2.2. Hysteroscopy
  - 7.7.2.3. Dilation and curettage
- 7.7.3. Blood tests
  - 7.7.3.1. Complete blood Count
  - 7.7.3.2. CA-125 blood test
7.8. Historical Market Size Analysis 2019 - 2024, By End User
- 7.8.1. Hospitals
- 7.8.2. Ambulatory Surgical Centers
- 7.8.3. Cancer Research Centers
- 7.8.4. Specialized Clinics
- 7.8.5. Diagnostic Laboratories
- 7.8.6. Others
7.9. Market Size Analysis 2025 - 2032, By End User
- 7.9.1. Hospitals
- 7.9.2. Ambulatory Surgical Centers
- 7.9.3. Cancer Research Centers
- 7.9.4. Specialized Clinics
- 7.9.5. Diagnostic Laboratories
- 7.9.6. Others
7.10. Drivers and Restraints: Impact Analysis
7.11. Market Attractiveness Analysis
- 7.11.1. By Cancer Type
- 7.11.2. By Test Type
- 7.11.3. By End user
- 7.11.4. By Country

8. Asia Pacific Excluding China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

8.1. Introduction
8.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 8.2.1. China
- 8.2.2. India
- 8.2.3. Japan
- 8.2.4. Australia and New Zealand
- 8.2.5. Rest of APAC
8.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 8.3.1. China
- 8.3.2. India
- 8.3.3. Japan
- 8.3.4. Australia and New Zealand
- 8.3.5. Rest of APAC
8.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 8.4.1. Uterine Sarcoma
- 8.4.2. Endometrial Carcinomas
8.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 8.5.1. Uterine Sarcoma
- 8.5.2. Endometrial Carcinomas
8.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 8.6.1. Ultrasound Scanning
  - 8.6.1.1. Abdominal Ultrasound
  - 8.6.1.2. Transvaginal Ultrasound
- 8.6.2. Biopsy
  - 8.6.2.1. Endometrial Biopsy
  - 8.6.2.2. Hysteroscopy
  - 8.6.2.3. Dilation and curettage
- 8.6.3. Blood tests
  - 8.6.3.1. Complete blood Count
  - 8.6.3.2. CA-125 blood test
8.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 8.7.1. Ultrasound Scanning
  - 8.7.1.1. Abdominal Ultrasound
  - 8.7.1.2. Transvaginal Ultrasound
- 8.7.2. Biopsy
  - 8.7.2.1. Endometrial Biopsy
  - 8.7.2.2. Hysteroscopy
  - 8.7.2.3. Dilation and curettage
- 8.7.3. Blood tests
  - 8.7.3.1. Complete blood Count
  - 8.7.3.2. CA-125 blood test
8.8. Historical Market Size Analysis 2019 - 2024, By End User
- 8.8.1. Hospitals
- 8.8.2. Ambulatory Surgical Centers
- 8.8.3. Cancer Research Centers
- 8.8.4. Specialized Clinics
- 8.8.5. Diagnostic Laboratories
- 8.8.6. Others
8.9. Market Size Analysis 2025 - 2032, By End User
- 8.9.1. Hospitals
- 8.9.2. Ambulatory Surgical Centers
- 8.9.3. Cancer Research Centers
- 8.9.4. Specialized Clinics
- 8.9.5. Diagnostic Laboratories
- 8.9.6. Others
8.10. Drivers and Restraints: Impact Analysis
8.11. Market Attractiveness Analysis
- 8.11.1. By Cancer Type
- 8.11.2. By Test Type
- 8.11.3. By End user
- 8.11.4. By Country

9. China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

9.1. Introduction
9.2. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 9.2.1. Uterine Sarcoma
- 9.2.2. Endometrial Carcinomas
9.3. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 9.3.1. Uterine Sarcoma
- 9.3.2. Endometrial Carcinomas
9.4. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 9.4.1. Ultrasound Scanning
  - 9.4.1.1. Abdominal Ultrasound
  - 9.4.1.2. Transvaginal Ultrasound
- 9.4.2. Biopsy
  - 9.4.2.1. Endometrial Biopsy
  - 9.4.2.2. Hysteroscopy
  - 9.4.2.3. Dilation and curettage
- 9.4.3. Blood tests
  - 9.4.3.1. Complete blood Count
  - 9.4.3.2. CA-125 blood test
9.5. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 9.5.1. Ultrasound Scanning
  - 9.5.1.1. Abdominal Ultrasound
  - 9.5.1.2. Transvaginal Ultrasound
- 9.5.2. Biopsy
  - 9.5.2.1. Endometrial Biopsy
  - 9.5.2.2. Hysteroscopy
  - 9.5.2.3. Dilation and curettage
- 9.5.3. Blood tests
  - 9.5.3.1. Complete blood Count
  - 9.5.3.2. CA-125 blood test
9.6. Historical Market Size Analysis 2019 - 2024, By End User
- 9.6.1. Hospitals
- 9.6.2. Ambulatory Surgical Centers
- 9.6.3. Cancer Research Centers
- 9.6.4. Specialized Clinics
- 9.6.5. Diagnostic Laboratories
- 9.6.6. Others
9.7. Market Size Analysis 2025 - 2032, By End User
- 9.7.1. Hospitals
- 9.7.2. Ambulatory Surgical Centers
- 9.7.3. Cancer Research Centers
- 9.7.4. Specialized Clinics
- 9.7.5. Diagnostic Laboratories
- 9.7.6. Others
9.8. Drivers and Restraints: Impact Analysis
9.9. Market Attractiveness Analysis
- 9.9.1. By Cancer Type
- 9.9.2. By Test Type
- 9.9.3. By End user
- 9.9.4. By Country

10. Middle East and Africa (MEA) Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

10.1. Introduction
10.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
- 10.2.1. South Africa
- 10.2.2. Saudi Arabia
- 10.2.3. Rest of MEA
10.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
- 10.3.1. South Africa
- 10.3.2. Saudi Arabia
- 10.3.3. Rest of MEA
10.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
- 10.4.1. Uterine Sarcoma
- 10.4.2. Endometrial Carcinomas
10.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
- 10.5.1. Uterine Sarcoma
- 10.5.2. Endometrial Carcinomas
10.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
- 10.6.1. Ultrasound Scanning
  - 10.6.1.1. Abdominal Ultrasound
  - 10.6.1.2. Transvaginal Ultrasound
- 10.6.2. Biopsy
  - 10.6.2.1. Endometrial Biopsy
  - 10.6.2.2. Hysteroscopy
  - 10.6.2.3. Dilation and curettage
- 10.6.3. Blood tests
  - 10.6.3.1. Complete blood Count
  - 10.6.3.2. CA-125 blood test
10.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
- 10.7.1. Ultrasound Scanning
  - 10.7.1.1. Abdominal Ultrasound
  - 10.7.1.2. Transvaginal Ultrasound
- 10.7.2. Biopsy
  - 10.7.2.1. Endometrial Biopsy
  - 10.7.2.2. Hysteroscopy
  - 10.7.2.3. Dilation and curettage
- 10.7.3. Blood tests
  - 10.7.3.1. Complete blood Count
  - 10.7.3.2. CA-125 blood test
10.8. Historical Market Size Analysis 2019 - 2024, By End User
- 10.8.1. Hospitals
- 10.8.2. Ambulatory Surgical Centers
- 10.8.3. Cancer Research Centers
- 10.8.4. Specialized Clinics
- 10.8.5. Diagnostic Laboratories
- 10.8.6. Others
10.9. Market Size Analysis 2025 - 2032, By End User
- 10.9.1. Hospitals
- 10.9.2. Ambulatory Surgical Centers
- 10.9.3. Cancer Research Centers
- 10.9.4. Specialized Clinics
- 10.9.5. Diagnostic Laboratories
- 10.9.6. Others
10.10. Drivers and Restraints: Impact Analysis
10.11. Market Attractiveness Analysis
- 10.11.1. By Cancer Type
- 10.11.2. By Test Type
- 10.11.3. By End user
- 10.11.4. By Country

11. Forecast Factors: Relevance and Impact

12. Competition Landscape

12.1. Competition Dashboard
12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3. Key Players
- 12.3.1. Abbott
- 12.3.2. Roche Holdings AG
- 12.3.3. Siemens AG
- 12.3.4. Danaher
- 12.3.5. BioMerieux SA

13. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

13.1. Introduction
- 13.1.1. Basis Point Share (BPS) Analysis by Region
- 13.1.2. Y-o-Y Growth Projections by Region
13.2. Historical Market Size Analysis 2019 - 2024, By Region
- 13.2.1. North America
- 13.2.2. Latin America
- 13.2.3. Europe
- 13.2.4. Asia Pacific Excluding China
- 13.2.5. China
- 13.2.6. Middle East and Africa (MEA)
13.3. Market Size Analysis 2025 - 2032, By Region
- 13.3.1. North America
- 13.3.2. Latin America
- 13.3.3. Europe
- 13.3.4. Asia Pacific Excluding China
- 13.3.5. China
- 13.3.6. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis by Region

14. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Cancer Type

14.1. Introduction
- 14.1.1. Basis Point Share (BPS) Analysis by Product Type
- 14.1.2. Y-o-Y Growth Projections by Product Type
14.2. Historical Market Size Analysis 2019 - 2024, By Cancer Type
- 14.2.1. Uterine Sarcoma
- 14.2.2. Endometrial Carcinomas
14.3. Market Size Analysis 2025 - 2032, By Cancer Type
- 14.3.1. Uterine Sarcoma
- 14.3.2. Endometrial Carcinomas
14.4. Market Attractiveness Analysis by Cancer Type

15. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Diagnostic Test Type

15.1. Introduction
- 15.1.1. Basis Point Share (BPS) Analysis by Test Type
- 15.1.2. Y-o-Y Growth Projections by Test Type
15.2. Historical Market Size Analysis 2019 - 2024, By Test Type
- 15.2.1. Ultrasound Scanning
  - 15.2.1.1. Abdominal Ultrasound
  - 15.2.1.2. Transvaginal Ultrasound
- 15.2.2. Biopsy
  - 15.2.2.1. Endometrial Biopsy
  - 15.2.2.2. Hysteroscopy
  - 15.2.2.3. Dilation and curettage
- 15.2.3. Blood tests
  - 15.2.3.1. Complete blood Count
  - 15.2.3.2. CA-125 blood test
15.3. Market Size Analysis 2025 - 2032, By Test Type
- 15.3.1. Ultrasound Scanning
  - 15.3.1.1. Abdominal Ultrasound
  - 15.3.1.2. Transvaginal Ultrasound
- 15.3.2. Biopsy
  - 15.3.2.1. Endometrial Biopsy
  - 15.3.2.2. Hysteroscopy
  - 15.3.2.3. Dilation and curettage
- 15.3.3. Blood tests
  - 15.3.3.1. Complete blood Count
  - 15.3.3.2. CA-125 blood test
15.4. Market Attractiveness Analysis by Test Type

16. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By End User

16.1. Introduction
- 16.1.1. Basis Point Share (BPS) Analysis by End User
- 16.1.2. Y-o-Y Growth Projections by End User
16.2. Historical Market Size Analysis 2019 - 2024, By End User
- 16.2.1. Hospitals
- 16.2.2. Ambulatory Surgical Centers
- 16.2.3. Cancer Research Centers
- 16.2.4. Specialized Clinics
- 16.2.5. Diagnostic Laboratories
- 16.2.6. Others
16.3. Market Size Analysis 2025 - 2032, By End User
- 16.3.1. Hospitals
- 16.3.2. Ambulatory Surgical Centers
- 16.3.3. Cancer Research Centers
- 16.3.4. Specialized Clinics
- 16.3.5. Diagnostic Laboratories
- 16.3.6. Others
16.4. Market Attractiveness Analysis by End User

17. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

17.1. Market Size and Y-o-Y Growth
17.2. Absolute $ Opportunity

18. Assumptions and Acronyms Used

A glossary of assumption and acronyms used in the report

한글목차

목차

제1장 주요 요약

제2장 시장 소개

제3장 자궁암 진단 검사 시장의 시점

제4장 세계의 자궁암 진단 검사 시장- 주요 조사 내용

제5장 북미의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제6장 라틴아메리카의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제7장 유럽의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제8장 중국을 제외한 아시아태평양의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제9장 중국의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제10장 중동 및 아프리카의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제11장 예측 요인: 관련성과 영향

제12장 경쟁 구도

제13장 세계의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년), 지역별

제14장 세계의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년), 암 유형별

제15장 세계의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년), 진단 검사 유형별

제16장 세계의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년), 최종 사용자별

제17장 세계의 자궁암 진단 검사 시장 분석(2019-2024년) 및 예측(2025-2032년)

제18장 사용된 전제조건과 약어

제19장 조사 방법